--Berenberg Bank Adjusts Glaukos' Price Target to $68 From $90, Maintains Buy Rating
MT Newswires · 2d ago
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release · 3d ago
--Citigroup Adjusts Glaukos' Price Target to $52 From $94, Maintains Neutral Rating
MT Newswires · 4d ago
Glaukos Corporation (GKOS): Are Hedge Funds Right About This Stock?
Is Glaukos Corporation (NYSE:GKOS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are ...
Insider Monkey · 4d ago
Stephens & Co. Downgrades Glaukos to Equal-Weight, Announces $70 Price Target
Stephens & Co. analyst Chris Cooley downgrades Glaukos (NYSE:GKOS) from Overweight to Equal-Weight and announces $70 price target.
Benzinga · 6d ago
Stephens Downgrades Glaukos to Equal-Weight From Overweight; Price Target is $70
MT Newswires · 6d ago
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in variou...
Business Wire · 07/22 11:00
Why Glaukos Shares Dipped Today
Glaukos (NYSE: GKOS) shares are trading lower after Wells Fargo downgraded the stock from Equal-Weight to Underweight. 
Benzinga · 07/20 19:40
NeuroBo Pharmaceuticals, NeuroMetrix leads healthcare gainers; Ardelyx, Allied Healthcare Products among major losers
Gainers: NeuroBo Pharmaceuticals (NRBO) +50%, NeuroMetrix NURO +41%, Immunome IMNM +31%, Endo International (ENDP) +21%, PLx Pharma (PLXP) +18%.Losers: Ardelyx ARDX -75%, Allied Healthcare Products (AHPI) -22%, NRx Pharmaceuticals (NRXP) -13%, China SXT Ph...
Seekingalpha · 07/20 15:00
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021
Benzinga · 07/20 14:14
Glaukos slumps as Wells Fargo downgrades stock on reimbursement concerns
Glaukos Corporation (GKOS) has lost ~13.0% in the pre-market after Wells Fargo Securities downgraded the stock to underweight from equal-weight, citing the headwinds to the top-line from the proposed reimbursement cuts to
Seekingalpha · 07/20 12:20
Wells Fargo Downgrades Glaukos to Underweight From Equal-Weight; Price Target is $41
MT Newswires · 07/20 05:56
Moderna headlines weekly healthcare gainers; FibroGen and Biogen trail
Artystarty/iStock via Getty Images Thanks to the prospects of earning a spot in the S&P 500 Index, Moderna (MRNA) jumped ~23.0% this week to breeze past $100B market capitalization. The frontrunner in COVID-19 vaccine development
Seekingalpha · 07/18 01:04
Teleflex and Itamar sell off “too draconian”: Piper Sandler
Wolterk/iStock Editorial via Getty Images Teleflex Incorporated (TFX) and Itamar Medical (ITMR) fell sharply on Thursday after the newly released reimbursement, rates published by the Centers for Medicare and Medicaid
Seekingalpha · 07/16 20:57
Berenberg Bank Adjusts Glaukos PT to $90 From $103, Maintains Buy Rating
MT Newswires · 07/16 13:06
Glaukos (GKOS) is Oversold: Can It Recover?
Glaukos (GKOS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 07/16 10:14
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the...
Business Wire · 07/15 20:15
Hot Stocks: A bummer for cannabis stocks; CPLG for sale; GKOS reimbursements; JEF gets investment; CPOP keeps falling
naphtalina/iStock via Getty Images Federal Reserve Chairman Jerome Powell may have dominated headlines throughout Wednesday's session. But Wall Street still saw a few standout performances that had little to do
Seekingalpha · 07/14 21:57
Mid-Afternoon Market Update: Dow Gains 50 Points; Imara Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 0.15% to 34,942.77 while the NASDAQ rose 0.07% to 14,687.21. The S&P also rose, gaining 0.26% to 4,380.58.
Benzinga · 07/14 18:29
SNQA, USEG, HNRG among mid-day movers
Gainers: U.S. Energy (USEG) +73%.Wilhelmina International (WHLM) +50%.SGOCO Group (SGOC) +41%.Datasea (DTSS) +43%.Westwood Holdings (WHG) +20%.CorePoint Lodging (CPLG) +19%.AcelRx Pharmaceuticals (ACRX) +17%.Marine Petroleum Trust (MARPS) +14%.Verb Technol...
Seekingalpha · 07/14 16:52
Webull provides a variety of real-time GKOS stock news. You can receive the latest news about Glaukos through multiple platforms. This information may help you make smarter investment decisions.
About GKOS
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.